Ionis Pharmaceuticals, Inc.
IONSIonis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
Drugs in Pipeline
42
Phase 3 Programs
10
Upcoming Catalysts
5
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
6 upcoming, 0 past
How IONS's past catalysts played out
ION363
Amyotrophic Lateral Sclerosis
Donidalorsen
Hereditary Angioedema
Alicaforsen
Ulcerative Colitis
Olezarsen
Familial Chylomicronemia Syndrome
zilganersen
Alexander Disease
ISIS 3521
Lung Cancer
Inotersen
FAP
ION582
Angelman Syndrome
Eplontersen
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Volanesorsen
Familial Chylomicronemia Syndrome
ISIS-PTP1BRx
Type 2 Diabetes Mellitus
ION904
Hypertension
ISIS 104838
Rheumatoid Arthritis
IONIS-DMPKRx
Myotonic Dystrophy Type 1
Fomivirsen sodium
Cytomegalovirus Retinitis
ISIS apoC-III Rx
Hypertriglyceridemia
ION-682884
Healthy Volunteers
ISIS 14803
Hepatitis C, Chronic
ISIS-GCGRRx- Dose Level 1
Type 2 Diabetes
ISIS-FGFR4RX
Obesity
ISIS CRP Rx
Paroxysmal Atrial Fibrillation
IONIS DGAT2Rx
Hepatic Steatosis
sapablursen
Phlebotomy Dependent Polycythemia Vera
IONIS-FB-LRx
Macular Degeneration
IONIS-GHR-LRx
Acromegaly
IONIS-STAT3Rx
Advanced Cancers
IONIS-AGT-LRx
Chronic Heart Failure With Reduced Ejection Fraction
IONIS GHR-LRx
Acromegaly
GHR-LRX
Acromegaly
ISIS-FXIRx Dose #2
Venous Thromboembolism
ION440
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
ISIS-GCGRRx
Type 2 Diabetes
ISIS-GCGRRx - Dose Level 1
Type 2 Diabetes Mellitus
ISIS-APO(a)Rx
Elevated Lipoprotein(a)
ION224
Steatohepatitis, Nonalcoholic
ISIS 443139 10 mg
Huntington's Disease
ISIS 113715
Type 2 Diabetes Mellitus
ISIS-GCCRRx
Type 2 Diabetes Mellitus
ISIS EIF4E Rx
Castrate-Resistant Prostate Cancer
ISIS 757456
Mild Hypertension
ISIS 416858
End-stage Renal Disease (ESRD)
ION717
Prion Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ION363 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
Donidalorsen | Phase 3 | Hereditary Angioedema | - | - |
Alicaforsen | Phase 3 | Ulcerative Colitis | - | - |
Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome | - | Patent 2034 |
zilganersen | Phase 3 | Alexander Disease | - | - |
ISIS 3521 | Phase 3 | Lung Cancer | - | - |
Inotersen | Phase 3 | FAP | - | Patent 2031 |
ION582 | Phase 3 | Angelman Syndrome | - | - |
Eplontersen | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | - | Patent 2034 |
Volanesorsen | Phase 3 | Familial Chylomicronemia Syndrome | - | - |
ISIS-PTP1BRx | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ION904 | Phase 2 | Hypertension | - | - |
ISIS 104838 | Phase 2 | Rheumatoid Arthritis | - | - |
IONIS-DMPKRx | Phase 2 | Myotonic Dystrophy Type 1 | - | - |
Fomivirsen sodium | Phase 2 | Cytomegalovirus Retinitis | - | |
ISIS apoC-III Rx | Phase 2 | Hypertriglyceridemia | - | - |
ION-682884 | Phase 2 | Healthy Volunteers | - | - |
ISIS 14803 | Phase 2 | Hepatitis C, Chronic | - | - |
ISIS-GCGRRx- Dose Level 1 | Phase 2 | Type 2 Diabetes | - | - |
ISIS-FGFR4RX | Phase 2 | Obesity | - | - |
ISIS CRP Rx | Phase 2 | Paroxysmal Atrial Fibrillation | - | - |
IONIS DGAT2Rx | Phase 2 | Hepatic Steatosis | - | - |
sapablursen | Phase 2 | Phlebotomy Dependent Polycythemia Vera | - | - |
IONIS-FB-LRx | Phase 2 | Macular Degeneration | - | - |
IONIS-GHR-LRx | Phase 2 | Acromegaly | - | - |
IONIS-STAT3Rx | Phase 2 | Advanced Cancers | - | - |
IONIS-AGT-LRx | Phase 2 | Chronic Heart Failure With Reduced Ejection Fraction | - | - |
IONIS GHR-LRx | Phase 2 | Acromegaly | - | - |
GHR-LRX | Phase 2 | Acromegaly | - | - |
ISIS-FXIRx Dose #2 | Phase 2 | Venous Thromboembolism | - | - |
ION440 | Phase 2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | - | - |
ISIS-GCGRRx | Phase 2 | Type 2 Diabetes | - | - |
ISIS-GCGRRx - Dose Level 1 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS-APO(a)Rx | Phase 2 | Elevated Lipoprotein(a) | - | - |
ION224 | Phase 2 | Steatohepatitis, Nonalcoholic | - | - |
ISIS 443139 10 mg | Phase 2 | Huntington's Disease | - | - |
ISIS 113715 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS-GCCRRx | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS EIF4E Rx | Phase 2 | Castrate-Resistant Prostate Cancer | - | - |
ISIS 757456 | Phase 2 | Mild Hypertension | - | - |
ISIS 416858 | Phase 2 | End-stage Renal Disease (ESRD) | - | - |
ION717 | Phase 2 | Prion Disease | - | - |
Type 2 Diabetes Mellitus
4 drugs in this indication
Acromegaly
2 drugs in this indication
Familial Chylomicronemia Syndrome
2 drugs in this indication
Hypertension
2 drugs in this indication
Alexander disease
2 drugs in this indication
Rheumatoid Arthritis
2 drugs in this indication
Steatohepatitis, Nonalcoholic
1 drug in this indication
Angelman Syndrome
1 drug in this indication
Obesity
1 drug in this indication
Elevated Lipoprotein(a)
1 drug in this indication
Mild Hypertension
1 drug in this indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
1 drug in this indication
Huntington's Disease
1 drug in this indication
Amyotrophic Lateral Sclerosis
1 drug in this indication
FAP
1 drug in this indication
Paroxysmal Atrial Fibrillation
1 drug in this indication
Phlebotomy Dependent Polycythemia Vera
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Castrate-Resistant Prostate Cancer
1 drug in this indication
Hepatic Steatosis
1 drug in this indication
Macular Degeneration
1 drug in this indication
End-stage Renal Disease (ESRD)
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
Hereditary Angioedema
1 drug in this indication
Advanced Cancers
1 drug in this indication
Hypertriglyceridemia
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Chronic Heart Failure With Reduced Ejection Fraction
1 drug in this indication
Cytomegalovirus Retinitis
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Myotonic Dystrophy Type 1
1 drug in this indication
Prion Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ionis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 42 drug candidates in Ionis Pharmaceuticals, Inc.'s (IONS) pipeline across Phase 3, Phase 2. Its lead program is ION363 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ionis Pharmaceuticals, Inc.'s next FDA catalyst?→
Ionis Pharmaceuticals, Inc.'s (IONS) next tracked catalyst is a Phase 1 expected February 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IONS biotech catalysts?→
Add IONS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ionis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.